Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Gilead Sciences

These big biotechs are both moving into new areas. Which is most likely to move the needle for investors?

Better Buy: Gilead Sciences vs. Amgen

The company has had some challenges.  But when looking at the long-term, Amgen stock looks like a good play.

3 Reasons To Be Bullish On Biotech Giant Amgen

AmerisourceBergen

Extra Space Storage

Group 1 Automotive

Stocks include a new addition to the gurus' list of good companies

5 Buffett-Munger Stocks With High Dividend Yields

Alexion Pharma

Biogen

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The short interest data are out for September 15, the most recent settlement date.

Biotech Short Sellers Hike Their Bets

In 2020 investors have been forced to dial down expectations in biotech if their business ambitions are not tied to COVID-19.

Why Amgen Is Called to Outperform Large-Cap Biotechs

BioNTech SE

Sanofi

Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.

Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch

Prudential Financial

Snap-on

T. Rowe Price Group

Texas Instruments

The core of a dividend portfolio should be made of all weather dividend stocks.

The 5 Undervalued Blue Chip High Dividend Growth Stocks You Need To Buy Now

THOUSAND OAKS, Calif., Sept. 20, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 129 patients across multiple advanced solid tumors, were...

Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine

Amgen: Growing At A Reasonable Price

AstraZeneca

Pfizer

Coronavirus concerns seem to be lifting as the markets churn higher, but is this a carrot-or-the-stick question?

This Week in Coronavirus News

While the biotech stares down a busy year ahead, shareholders should buckle up for an exciting ride.

Where Will Amgen Be in 1 Year?

Eli Lilly

Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.

Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies

Eli Lilly and Amgen on Thursday announced they will team up to manufacture and distribute Lilly's Covid-19 treatments worldwide, if the treatments get approved, and Eli Lilly stock edged up.
The post Eli Lilly, Amgen Teaming Up On Covid-19 Treatments appeared first on Investor's Business Daily.

Eli Lilly, Amgen Teaming Up On Covid-19 Treatments

Eli Lilly and Co. LLY, +0.58% and Amgen Inc. AMGN, -0.23% said Thursday they will collaborate on COVID-19 antibody treatments as a way to significantly boost global supply capacity.

Eli Lilly and Amgen to collaborate on COVID-19 antibody therapies

INDIANAPOLIS and THOUSAND OAKS, Calif., Sept. 17, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly's potential COVID-19 therapies.

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Amgen Inc. (AMGN) Management Presents at Morgan Stanley's 18th Annual Virtual Global Healthcare Conference (Transcript)

THOUSAND OAKS, Calif., Sept. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host two webcast calls for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.

Amgen To Webcast Investor Calls At ESMO 2020

THOUSAND OAKS, Calif., Sept. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that data from its oncology pipeline in solid tumors will be presented during the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Sept.

Amgen To Showcase Data From Oncology Pipeline During ESMO Virtual Congress 2020

Salesforce

Home Depot

McDonald's

UnitedHealth Group

Hint: Apple and Microsoft aren't on the list.

The Dow Jones' 5 Most Important Stocks

These stocks are great anchors for any healthcare investor's portfolio.

2 No-Brainer Stocks to Buy in Biotech

These drug giants are gearing up for a profitable 2021.

2 No-Brainer Stocks to Buy In Pharma

THOUSAND OAKS, Calif., Sept. 11, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 18th Annual Virtual Global Healthcare Conference at 11:45 a.m.

Amgen To Present At The 18th Annual Morgan Stanley Global Healthcare Conference

The short interest data are out for August 31, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Short Sellers Hike Their Bets in Major Biotechs

AbbVie

GlaxoSmithKline

Johnson & Johnson

Merck

Novartis

Roche Holding AG

As evidence grew this spring that the drug remdesivir was helping COVID-19 patients, some Wall Street investors bet on analysts’ estimates that its maker, Gilead Sciences Inc , could charge up to $10,000 for the treatment.

Big Pharma wages stealth war on drug price watchdog

These two pharma giants are unlikely to cut their dividend payments during the next market correction.

News for Amgen Stock (AMGN)